Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,867 matching trials from the live ClinicalTrials.gov search.
Conditions
Pediatric Crohn's Disease
Interventions
Methotrexate, Sugar pill (placebo)
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Up to 20 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
32
States / cities
Birmingham, Alabama • Alto, California • New Haven, Connecticut + 27 more
Completed No phase listed Observational Accepts healthy volunteers Results available

Examining Cognitive Function and Brain Abnormalities in Adults With Sickle Cell Disease

NCT00528801
Conditions
Anemia, Sickle Cell
Interventions
NP Battery, MRI
Behavioral · Procedure
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
21 Years to 55 Years
Enrollment
212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
12
States / cities
Los Angeles, California • Oakland, California • Hollywood, Florida + 8 more
Conditions
Brain Lesions, Brain Metastasis, Brain Metastases
Interventions
FLT PET/MR
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Leukemia
Interventions
mercaptopurine, methotrexate, tretinoin
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
210
States / cities
Scottsdale, Arizona • Roseville, California • Sacramento, California + 135 more
Conditions
HIV Infections
Interventions
Indinavir sulfate, Amprenavir, Nelfinavir mesylate, Saquinavir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
San Diego, California • San Francisco, California • Durham, North Carolina
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Incidental Findings Information on Lung Cancer Screening Intent

NCT04432753
Conditions
Neoplasm of Lung, Decision Support Techniques, Mass Screening
Interventions
Lung Cancer Screening Decision Aid with Incidental Findings Information, Lung Cancer Screening Decision Aid without Incidental Findings Information
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
55 Years to 80 Years
Enrollment
419 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Epilepsy; Seizure, Neuromuscular Diseases, Brain Malformation, Intellectual Disability, Autism Spectrum Disorder, Hypotonia, Inborn Errors of Metabolism, Movement Disorders, Genetic Disease, Development Delay, Chromosome Abnormality, Hearing Loss, Dysmorphic Features, Skeletal Dysplasia, Congenital Abnormality, Microcephaly, Macrocephaly
Interventions
Pre-visit prep, usual care + exome seq
Behavioral · Diagnostic Test
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
0 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Asheville, North Carolina • Chapel Hill, North Carolina • Greenville, North Carolina
Recruiting Not applicable Interventional

Zenith® Fenestrated+ Clinical Study

NCT04875429
Conditions
Aortic Aneurysm, Abdominal, Juxtarenal Aortic Aneurysm, Extent IV Thoracoabdominal, Pararenal Aneurysm
Interventions
Zenith Fenestrated+ Endovascular Graft in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System and Unibody2
Device
Lead sponsor
Cook Research Incorporated
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
32
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 27 more
Conditions
Children's Health and Growth, Childcare Absenteeism
Interventions
Yogurt drink with probiotic bacteria BB12, Placebo
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Months to 48 Months
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Cerebral Concussion
Interventions
ACTIVE Training
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 30 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Degenerative and Traumatic Pathology of the Knee, Degenerative and Traumatic Pathology of the Shoulder and Elbow, Degenerative and Traumatic Pathology of the Foot and Ankle, Degenerative and Traumatic Pathology of the Hand and Wrist, Degenerative and Traumatic Pathology of the Hip
Interventions
Not listed
Lead sponsor
Arthrex, Inc.
Industry
Eligibility
12 Years and older
Enrollment
12,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
220
States / cities
Birmingham, Alabama • Montgomery, Alabama • Anchorage, Alaska + 171 more
Conditions
Cystic Fibrosis, Pulmonary Disease, Chronic Obstructive
Interventions
Tobramycin solution for inhalation (TOBI), Oral placebo, Oral ciprofloxacin
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Year to 12 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
54
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 49 more
Conditions
Angelman Syndrome
Interventions
rugonersen, Sham procedure
Drug · Procedure
Lead sponsor
OHB Pediatrics Ltd.
Industry
Eligibility
1 Year to 50 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
7
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 4 more
Conditions
Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA, Acute Promyelocytic Leukemia
Interventions
QTX-2101 + ATRA, IV arsenic trioxide (ATO) + ATRA
Drug
Lead sponsor
Quetzal Therapeutics
Industry
Eligibility
18 Years to 71 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
18
States / cities
Birmingham, Alabama • Duarte, California • Irvine, California + 14 more
Conditions
HIV-1-infection
Interventions
MGD014
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Prostate Cancer
Interventions
Atrasentan
Drug
Lead sponsor
Abbott
Industry
Eligibility
19 Years and older · Male only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
79
States / cities
Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 66 more
Completed Phase 2 Interventional Results available

Ruxolitinib for Premalignant Breast Disease

NCT02928978
Conditions
Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma In Situ
Interventions
Ruxolitinib, Placebo (for Ruxolitinib)
Drug
Lead sponsor
Julie Nangia
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Indianapolis, Indiana • The Bronx, New York + 3 more
Completed Not applicable Interventional Accepts healthy volunteers

Making Effective Human Papillomavirus (HPV) Vaccine Recommendations

NCT02377843
Conditions
Human Papillomavirus
Interventions
Participatory, Efficient
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Nutrition, Type 2 Diabetes, T2DM, T2DM (Type 2 Diabetes Mellitus), Diabetes Education, Diabetes Type 2, Diabetes Mellitis
Interventions
CGM-Augmented FIM, FIM only
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Inflammation, Periodontitis
Interventions
Sonicare/Elite-Flexcare Toothbrush, Manual Toothbrush
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 75 Years
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Acute HIV Infection, HIV Infections
Interventions
Darunavir, Ritonavir, Etravirine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Active, not recruiting Phase 1 Interventional Results available

Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

NCT02663297
Conditions
Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
Interventions
ATLCAR.CD30 cells
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
3 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2037
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Conditions
Small Cell Lung Cancer
Interventions
Tarlatamab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
U.S. locations
9
States / cities
New Haven, Connecticut • Miami Beach, Florida • Stuart, Florida + 6 more
Conditions
Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelomonocytic Leukemia
Interventions
Clofarabine
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina